2. Search Result
Search Result
Results for "

Diabetes rats

" in MedChemExpress (MCE) Product Catalog:

87

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

9

Peptides

1

Inhibitory Antibodies

24

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0442
    Vardenafil
    5 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil
  • HY-P10745
    Petrelintide

    ZP8396

    		 Amylin Receptor Metabolic Disease
    Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
    Petrelintide
  • HY-P10745A
    Petrelintide acetate

    ZP8396 acetate

    		 Amylin Receptor Metabolic Disease
    Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
    Petrelintide acetate
  • HY-134433
    GDP-L-fucose

    		Endogenous Metabolite Metabolic Disease
    GDP-L-fucose is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides, providing the fucose moiety for the oligosaccharides.The formation of GDP-L-fucose occurs through two pathways, the major ab initio metabolic pathway and the minor remedial metabolic pathway. GDP-L-fucose is associated with diabetes in rats .
    GDP-L-fucose
  • HY-N6952
    Geraniol
    2 Publications Verification

    		 Environmental Pollutants Fungal Endogenous Metabolite Bacterial Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Geraniol is an olefin terpene with oral activity. Geraniol inhibits cell proliferation and promotes apoptosis. Geraniol has antibacterial, antifungal, antioxidant, anti-inflammatory and antitumor activities. Geraniol can be used to study diabetes .
    Geraniol
  • HY-P3479
    Insulin (swine)

    		Insulin Receptor Metabolic Disease
    Insulin (swine) is an orally active insulin derived from pigs. Insulin (swine) when administered orally acts as an antigen to reduce the severity of pancreatic lymphocyte infiltration, but has no metabolic effect on blood glucose levels. Insulin (swine) increases glucose oxidation, stimulates lipogenesis, and lowers blood glucose levels. Insulin (swine) can be used in diabetes research .
    Insulin (swine)
  • HY-113126
    3-Hydroxyisobutyric acid

    		Endogenous Metabolite ATP Synthase Neurological Disease Metabolic Disease
    3-Hydroxyisobutyric acid is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .
    3-Hydroxyisobutyric acid
  • HY-B0481
    Miglitol
    2 Publications Verification

    BAY1099; BAY-m1099

    		 Glycosidase AMPK Reactive Oxygen Species (ROS) Metabolic Disease
    Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .
    Miglitol
  • HY-P3247
    [D-Ala2]-GIP (human)

    		Insulin Receptor Neurological Disease Metabolic Disease
    [D-Ala2]-GIP (human) is a GIP receptor agonist (EC50 = 630 pM). [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP (HY-W114750)-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
    [D-Ala2]-GIP (human)
  • HY-B0442A
    Vardenafil hydrochloride
    5 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-N0807
    Swertiamarin
    1 Publications Verification

    		 MMP NF-κB JAK Keap1-Nrf2 Metabolic Disease Inflammation/Immunology Cancer
    Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .
    Swertiamarin
  • HY-P990125
    Anti-Mouse CSF1R/CD115 Antibody (AFS98)

    		c-Fms Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Anti-Mouse (CSF1R/CD115) Antibody (AFS98) is an anti-mouse CSF1R IgG2a antibody inhibitor derived from rats. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) inhibits M-CSF-dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) can be used for the researches of inflammation, metabolic disease, cardiovascular disease and neurological disease, such as such as stroke, diabetes and arthritis .
    Anti-Mouse CSF1R/CD115 Antibody (AFS98)
  • HY-W027553
    Ipidacrine

    NIK-247 free base; Amiridine free base

    		 Cholinesterase (ChE) Potassium Channel Sodium Channel Neurological Disease Metabolic Disease
    Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K + and Na +-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .
    Ipidacrine
  • HY-B0442B
    Vardenafil hydrochloride trihydrate
    5 Publications Verification

    		 Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride trihydrate
  • HY-B1363
    Bendroflumethiazide

    Bendrofluazide

    		 NKCC Cardiovascular Disease
    Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide
  • HY-N7690
    3,5,7,3′,4′-Pentamethoxyflavone

    		Calcium Channel Cardiovascular Disease Metabolic Disease
    3,5,7,3’,4’-Pentamethoxyflavone is a Ca 2+ channel inhibitor. 3,5,7,3’,4’-Pentamethoxyflavone can protect DNA from oxidative damage. 3,5,7,3’,4’-Pentamethoxyflavone can induce relaxation of the human corpus cavernosum through calcium mobilization-related mechanisms. 3,5,7,3’,4’-Pentamethoxyflavone can promote the expression of eNOS and cystathionine gamma lyase CSE proteins in middle-aged male rats and regulate vascular function. 3,5,7,3’,4’-Pentamethoxyflavone can be used in research related to diabetes and cardiovascular diseases .
    3,5,7,3′,4′-Pentamethoxyflavone
  • HY-W145482
    3-O-Methyl-D-glucopyranose

    		Drug Isomer Metabolic Disease
    3-O-Methyl-D-glucopyranose is a non-metabolizable glucose analog. 3-O-Methyl-D-glucopyranose exerts a protective effect against alloxan-induced damage to rat pancreatic islet β cells. 3-O-Methyl-D-glucopyranose can be used in diabetes research .
    3-O-Methyl-D-glucopyranose
  • HY-N2896
    Arjunolic acid

    		Reactive Oxygen Species (ROS) Apoptosis Fungal Bacterial NF-κB SOD AMPK mTOR Notch Toll-like Receptor (TLR) Wnt MyD88 Sirtuin Infection Neurological Disease Inflammation/Immunology Cancer
    Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction .
    Arjunolic acid
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-135783
    AT 1001
    1 Publications Verification

    		 nAChR Neurological Disease Metabolic Disease Inflammation/Immunology
    AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease .
    AT 1001
  • HY-107482
    Picamilon

    Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid

    		 GABA Receptor Neurological Disease
    Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .
    Picamilon
  • HY-N8196
    Isorhamnetin 3,7-di-O-β-D-glucopyranoside

    Isorhamnetin-3,7-diglucoside; Isorhamnetin diglucoside

    		 Mitochondrial Metabolism Metabolic Disease
    Isorhamnetin 3,7-di-O-β-D-glucopyranoside, a major flavonoid compound, is metabolized in vivo by intestinal bacteria to isorhamnetin and that isorhamnetin plays an important role as an antioxidant .
    Isorhamnetin 3,7-di-O-β-D-glucopyranoside
  • HY-W020086
    2,3-Diaminophenazine

    2,3-Phenazinediamine; NNC39-0028

    		 DNA Alkylator/Crosslinker Fluorescent Dye Metabolic Disease
    2,3-Diaminophenazine (2,3-Phenazinediamine) is an orally active amino derivative of phenazine. 2,3-Diaminophenazine can intercalate into DNA. 2,3-Diaminophenazine triggers photochemical reactions. 2,3-Diaminophenazine inhibits vascular hypertrophy and tissue AGE deposition in diabetic rats. 2,3-Diaminophenazine can be used for luminescence and diabetes research .
    2,3-Diaminophenazine
  • HY-W142432
    Perfluoroundecanoic acid

    		Biochemical Assay Reagents β-catenin Wnt Arginase TGF-beta/Smad mTOR Akt ERK Atg8/LC3 p62 Autophagy Metabolic Disease Inflammation/Immunology Cancer
    Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation .
    Perfluoroundecanoic acid
  • HY-W984782
    Flindersine

    		GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD Infection Metabolic Disease Cancer
    Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .
    Flindersine
  • HY-119684
    Maresin 2

    		NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury .
    Maresin 2
  • HY-113266
    Valerylcarnitine
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine
  • HY-106181
    Rivoglitazone

    R-106056

    		 PPAR Cardiovascular Disease Metabolic Disease
    Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC50 of 0.22 μM for hPPARγ. Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A1C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes .
    Rivoglitazone
  • HY-N0469R
    L-Lysine (Standard)

    		Reference Standards Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
    L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
    L-Lysine (Standard)
  • HY-D0193A
    Ponceau 4R (85%)

    Acid Red 18 (85%); New Coccine (85%)

    		 Environmental Pollutants Drug Derivative Neurological Disease Inflammation/Immunology
    Ponceau 4R (85%) (Acid Red 18 (85%); New Coccine (85%)) is an orally active synthetic food colorant and a HSA-binding aggregator. Ponceau 4R (85%) binds to HSA, inducing its partial unfolding, conformational changes and aggregation. Ponceau 4R (85%) serves as a food colorant and can be used in research on diseases including type Ⅱ diabetes, Parkinson's disease, Huntington's disease and spongiform encephalopathy .
    Ponceau 4R (85%)
  • HY-164605
    (6S)-CP-470711

    		Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    (6S)-CP-470711 (Compound 8) is an inhibitor for sorbitol dehydrogenase, that inhibits human and rat SDH with IC50 of 19 nM and 27 nM. (6S)-CP-470711 ameliorates the Streptozotocin (HY-13753)-induced diabetes in rats models .
    (6S)-CP-470711
  • HY-100978
    (±)-Hexanoylcarnitine chloride

    DL-Hexanoylcarnitine chloride

    		 Endogenous Metabolite Metabolic Disease
    (±)-Hexanoylcarnitine chloride is a fatty acid metabolite that breaks down fatty acids into energy that can be used by the body. (±)-Hexanoylcarnitine chloride also serves as a specific and easily detectable biomarker for rat skeletal muscle toxicity. Cerivastatin (HY-129458) and TMPD (HY-W012145) induce an increase in Hexanoylcarnitine in rats in a metabolomic analysis of the rectus femoris muscle. In type 2 diabetes, Hexanoylcarnitine is also significantly associated with and improves prediction of all-cause mortality. Hexanoylcarnitine is a biomarker for the identification of novel pathogenic pathways .
    (±)-Hexanoylcarnitine chloride
  • HY-119741
    Salacinol

    		Glycosidase Lipase Metabolic Disease
    Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC50 = 3.2 μg/mL, Ki = 0.31 μg/mL), sucrase (IC50 = 0.84 μg/mL, Ki = 0.32 μg/mL), and isomaltase (IC50 = 0.59 μg/mL, Ki = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus .
    Salacinol
  • HY-101122
    LX2761

    		SGLT GLP Receptor Metabolic Disease
    LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research .
    LX2761
  • HY-107482A
    Picamilon sodium

    Nicotinoyl-GABA sodium; Nicotinoyl-γ-aminobutyric acid sodium; Sodium 4-(nicotinamido)butanoate

    		 GABA Receptor Neurological Disease
    Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .
    Picamilon sodium
  • HY-106915
    SG-210

    SPR 210

    		 Aldose Reductase Neurological Disease Metabolic Disease
    SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753)-induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications .
    SG-210
  • HY-B0442AS
    Vardenafil-d5 hydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil-d5 hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil-d5 hydrochloride
  • HY-160602
    CPL207280

    		Free Fatty Acid Receptor Metabolic Disease
    CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
    CPL207280
  • HY-100446
    NTU281

    		Glutaminase Apoptosis Metabolic Disease Inflammation/Immunology
    NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes .
    NTU281
  • HY-177297
    LCZ960

    NVP-LCZ960

    		 Glucokinase Metabolic Disease
    LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .
    LCZ960
  • HY-112488
    EXEL-0346

    		Glucosylceramide Synthase (GCS) Metabolic Disease
    EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC50 of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes .
    EXEL-0346
  • HY-172811
    DA-302168S

    		GCGR Metabolic Disease
    DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study .
    DA-302168S
  • HY-178447
    PPARγ agonist 20

    		PPAR Glutathione Peroxidase SOD TNF Receptor Interleukin Related NF-κB Infection Metabolic Disease Endocrinology
    PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .
    PPARγ agonist 20
  • HY-N7690R
    3,5,7,3′,4′-Pentamethoxyflavone (Standard)

    		Reference Standards Calcium Channel Cardiovascular Disease Metabolic Disease
    3,5,7,3’,4’-Pentamethoxyflavone is a Ca2+ channel inhibitor. 3,5,7,3’,4’-Pentamethoxyflavone can protect DNA from oxidative damage. 3,5,7,3’,4’-Pentamethoxyflavone can induce relaxation of the human corpus cavernosum through calcium mobilization-related mechanisms. 3,5,7,3’,4’-Pentamethoxyflavone can promote the expression of eNOS and cystathionine gamma lyase CSE proteins in middle-aged male rats and regulate vascular function. 3,5,7,3’,4’-Pentamethoxyflavone can be used in research related to diabetes and cardiovascular diseases .
    3,5,7,3′,4′-Pentamethoxyflavone (Standard)
  • HY-W027553R
    Ipidacrine (Standard)

    NIK-247 free base (Standard); Amiridine free base (Standard)

    		 Reference Standards Cholinesterase (ChE) Potassium Channel Sodium Channel Neurological Disease Metabolic Disease
    Ipidacrine (Standard) is the analytical reference standard of Ipidacrine. This product is used for research and analytical applications. Ipidacrine is orally active and blood-brain-barrier-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K + and Na +-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .
    Ipidacrine (Standard)
  • HY-12976
    DS-1558

    		G Protein-coupled Receptor Kinase (GRK) Metabolic Disease
    DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .
    DS-1558
  • HY-131528
    Tenilsetam

    CAS 997

    		 TNF Receptor Neurological Disease Metabolic Disease
    Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats .
    Tenilsetam
  • HY-131542
    APPA

    		Aldose Reductase Apoptosis Metabolic Disease
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research .
    APPA
  • HY-155553
    GPR119 agonist 2

    		GPR119 Metabolic Disease
    GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .
    GPR119 agonist 2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: